Immediate pain sensation is less with subcutaneous epoietin-β compared to subcutaneous darbepoietin-α

Clinical Nephrology

Volumn 72, Issue 3, 2009, Pages 177-180

  ter Wee, P M ^a   de Koter, Y ^a   van der Veer, O ^a   van Vliet, M H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic kidney disease; Darbepoietin ; Epoetin ; Pain sensation

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; INJECTION SITE PAIN; MALE; NOCICEPTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VERBAL PAIN SCORE; VISUAL ANALOG SCALE;

DOUBLE-BLIND METHOD; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; TIME FACTORS;

EID: 70350156860     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72177     Document Type: Article

References (10)

1. Frenken LA, van Lier HJ, Gerlag PG, den HM, Koene RA. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving hemodialysis. BMJ. 1991; 303: 288.
2. Frenken LA, van Lier HJ, Jordans JG, Leunissen KM, van LR, Verstappen VM, Koene RA. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis. 1993; 22: 553-556.
3. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009; 24: 348-354.
4. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 2759-2767.
5. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 1181-1191.
6. Schmitt CP, Nau B, Brummer C, Rosenkranz J, Schaefer F. Increased injection pain with darbepoetin-α compared to epoetin-β in pediatric dialysis patients. Nephrol Dial Transplant. 2006; 21: 3520-3524.
7. Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther. 2007; 29: 1368-1380.
8. Spinowitz BS, Pratt RD. Epoetin delta is effective for the management of anemia associated with chronic kidney disease. Curr Med Res Opin. 2006; 22: 2507-2513.
9. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin compared to citrate-buffered epoetin α and epoetin β. Clin Nephrol. 1998; 49: 41-44.
10. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol. 1992; 12: 68-72.